Discover how Avigen’s avidity-based platform accurately detects, sorts and isolates high-performing TCR T cells, revealing that avidity reliably predicts cytotoxic killing and T cell activation — delivering mechanistic insight that conventional cytotoxicity assays cannot provide. Download the full case study to learn how our approach enables faster, de-risked TCR T cell candidate selection for immunotherapy development.